Deutsche Bank’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,599
| Closed | -$43.3K | – | 3652 |
|
|
2025
Q1 | $43.3K | Buy |
7,599
+5,232
| +221% | +$67K | ﹤0.01% | 3401 |
|
|
2024
Q4 | $49.9K | Hold |
2,367
| – | – | ﹤0.01% | 3412 |
|
|
2024
Q3 | $63.7K | Buy |
2,367
+819
| +53% | +$24.1K | ﹤0.01% | 3314 |
|
|
2024
Q2 | $44.1K | Sell |
1,548
-728
| -32% | -$25.5K | ﹤0.01% | 3346 |
|
|
2024
Q1 | $96.5K | Buy |
2,276
+62
| +3% | +$2.79K | ﹤0.01% | 3187 |
|
|
2023
Q4 | $118K | Buy |
2,214
+70
| +3% | +$3.16K | ﹤0.01% | 3141 |
|
|
2023
Q3 | $92.2K | Buy |
2,144
+1,869
| +680% | +$86.2K | ﹤0.01% | 3195 |
|
|
2023
Q2 | $15.1K | Buy |
+275
| New | +$15.1K | ﹤0.01% | 3611 |
|
|
2022
Q2 | – | Sell |
-2,289
| Closed | -$142K | – | 4205 |
|
|
2022
Q1 | $142K | Sell |
2,289
-107
| -4% | -$6.33K | ﹤0.01% | 3440 |
|
|
2021
Q4 | $169K | Sell |
2,396
-97
| -4% | -$6.9K | ﹤0.01% | 3459 |
|
|
2021
Q3 | $174K | Buy |
2,493
+199
| +9% | +$15.8K | ﹤0.01% | 3637 |
|
|
2021
Q2 | $191K | Sell |
2,294
-197
| -8% | -$13.9K | ﹤0.01% | 3810 |
|
|
2021
Q1 | $136K | Sell |
2,491
-236
| -9% | -$11.5K | ﹤0.01% | 3819 |
|
|
2020
Q4 | $117K | Buy |
2,727
+808
| +42% | +$30.2K | ﹤0.01% | 3760 |
|
|
2020
Q3 | $58K | Buy |
1,919
+182
| +10% | +$6.12K | ﹤0.01% | 3812 |
|
|
2020
Q2 | $54K | Buy |
+1,737
| New | +$46.8K | ﹤0.01% | 3779 |
|
|
2019
Q4 | – | Sell |
-9
| Closed | – | – | 5042 |
|
|
2019
Q3 | $0 | Sell |
9
-24,109
| -100% | -$599K | ﹤0.01% | 5048 |
|
|
2019
Q2 | $481K | Buy |
24,118
+16,072
| +200% | +$471K | ﹤0.01% | 3294 |
|
|
2019
Q1 | $346K | Sell |
8,046
-2,856
| -26% | -$104K | ﹤0.01% | 3672 |
|
|
2018
Q4 | $344K | Sell |
10,902
-1,527
| -12% | -$60.2K | ﹤0.01% | 3566 |
|
|
2018
Q3 | $653K | Sell |
12,429
-7
| -0.1% | -$393 | ﹤0.01% | 3608 |
|
|
2018
Q2 | $665K | Sell |
12,436
-6,471
| -34% | -$331K | ﹤0.01% | 3687 |
|
|
2018
Q1 | $945K | Buy |
18,907
+16,580
| +713% | +$743K | ﹤0.01% | 3348 |
|
|
2017
Q4 | $76K | Buy |
2,327
+1,031
| +80% | +$34.8K | ﹤0.01% | 4329 |
|
|
2017
Q3 | $48K | Buy |
1,296
+1,295
| +129,500% | +$38.3K | ﹤0.01% | 4377 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 5000 |
|
|
2017
Q1 | $0 | Sell |
1
-26
| -96% | -$749 | ﹤0.01% | 4983 |
|
|
2016
Q4 | $0 | Buy |
27
+26
| +2,600% | +$661 | ﹤0.01% | 4970 |
|
|
2016
Q3 | $0 | Sell |
1
-3,712
| -100% | -$103K | ﹤0.01% | 5030 |
|
|
2016
Q2 | $106K | Buy |
3,713
+3,225
| +661% | +$103K | ﹤0.01% | 4082 |
|
|
2016
Q1 | $14K | Sell |
488
-337
| -41% | -$9.55K | ﹤0.01% | 4735 |
|
|
2015
Q4 | $28K | Sell |
825
-111
| -12% | -$3.8K | ﹤0.01% | 4643 |
|
|
2015
Q3 | $34K | Buy |
936
+131
| +16% | +$6.09K | ﹤0.01% | 4596 |
|
|
2015
Q2 | $45K | Sell |
805
-3,123
| -80% | -$178K | ﹤0.01% | 4634 |
|
|
2015
Q1 | $228K | Buy |
3,928
+3,914
| +27,957% | +$210K | ﹤0.01% | 3719 |
|
|
2014
Q4 | $0 | Buy |
+14
| New | +$667 | ﹤0.01% | 6218 |
|
|
2014
Q3 | – | Sell |
-13,432
| Closed | -$610K | – | 5957 |
|
|
2014
Q2 | $610K | Buy |
13,432
+11,124
| +482% | +$467K | ﹤0.01% | 3324 |
|
|
2014
Q1 | $109K | Buy |
2,308
+1,778
| +335% | +$80.9K | ﹤0.01% | 4193 |
|
|
2013
Q4 | $24K | Sell |
530
-4,602
| -90% | -$201K | ﹤0.01% | 4672 |
|
|
2013
Q3 | $203K | Buy |
5,132
+3,101
| +153% | +$122K | ﹤0.01% | 4112 |
|
|
2013
Q2 | $71K | Buy |
+2,031
| New | +$77.8K | ﹤0.01% | 4380 |
|
Other funds holding HBIO
AE
HP
GIM
MIM
Deutsche Bank's HBIO Position: Q2 2025 in Review
Deutsche Bank sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 7,599 shares — an estimated $43.3K sold.
Deutsche Bank first reported a position in HBIO in Q2 2013 and held it in 41 quarters. The position peaked at $945K in Q1 2018. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.
- Deutsche Bank reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
- Deutsche Bank sold 7,599 Harvard Bioscience shares in Q2 2025, an estimated $43.3K.
- Deutsche Bank first reported a position in Harvard Bioscience in Q2 2013 and held it in 41 quarters.
- Deutsche Bank's Harvard Bioscience position peaked at $945K in Q1 2018.
- 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.
Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.